Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent and Lilly Announce China Approval for Rituxan Biosimilar

publication date: Oct 12, 2020

Suzhou Innovent Bio and Eli Lilly announced their Rituxan biosimilar was approved in China for lymphoma and leukemia indications. Halpryza® (rituximab injection) is Innovent's fourth mAb approved for China use. It is a recombinant human/murine chimeric monoclonal antibody drug that was co-developed by Innovent and Lilly. The biosimilar is indicated for China patients with diffuse large b cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital